Authors
Loading...
Mendelian randomization reveals ACP6, AP1G2, and ANXA2 as therapeutic targets for retinitis pigmentosa, indicating new treatment pathways.
Jia et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: